公开(公告)号：US20160136211A1

公开(公告)日：2016-05-19

申请号：US14896913

申请日：2014-06-13

Applicant: VIRALYTICS LIMITED

Inventor： Darren Raymond Shafren ,  Gough AU ,  Hardev Pandha ,  Guy Simpson

IPC: A61K35/768 ,  A61K31/7068 ,  A61N5/10 ,  A61K31/407

CPC classification number: A61K35/768 ,  A61K31/407 ,  A61K31/7068 ,  A61N5/10 ,  C12N2770/32332

Abstract: The present invention relates to methods of treating bladder cancer with human enterovirus C (HEC) in combination with chemotherapy or radiation therapy. The present invention also relates to methods for increasing susceptibility of a cancer cell to infection by HEC.

Abstract translation: 本发明涉及与人肠病毒C（HEC）结合化疗或放射治疗治疗膀胱癌的方法。 本发明还涉及增加癌细胞对HEC感染的易感性的方法。

公开(公告)号：US20190134120A1

公开(公告)日：2019-05-09

申请号：US16054834

申请日：2018-08-03

Applicant: Viralytics Limited

Inventor： DARREN SHAFREN ,  Gough Au ,  Hardev Pandha ,  Guy Simpson

IPC: A61K35/768 ,  A61N5/10 ,  A61K31/407 ,  A61K31/7068

Abstract: The present invention relates to methods of treating bladder cancer with human enterovirus C (HEC) in combination with chemotherapy or radiation therapy. The present invention also relates to methods for increasing susceptibility of a cancer cell to infection by HEC.

公开(公告)号：US20190134119A1

公开(公告)日：2019-05-09

申请号：US15868805

申请日：2018-01-11

Applicant: Viralytics Limited

Inventor： Darren Shafren ,  Gough Geoffrey Au

IPC: A61K35/768 ,  C12N7/00 ,  A61K9/00 ,  A61K39/395

Abstract: The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.

公开(公告)号：US20170348366A1

公开(公告)日：2017-12-07

申请号：US15406459

申请日：2017-01-13

Applicant: VIRALYTICS LIMITED

Inventor： Darren R. Shafren

IPC: A61K35/768 ,  A61K9/00 ,  G01N33/50 ,  C12N7/00 ,  C12Q1/02

CPC classification number: A61K35/768 ,  A61K9/0019 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  C12Q1/025 ,  G01N33/5011

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

公开(公告)号：US20170000832A1

公开(公告)日：2017-01-05

申请号：US15121517

申请日：2015-02-27

Applicant: VIRALYTICS LIMITED

Inventor： Darren Shafren ,  Gough Geoffrey Au

IPC: A61K35/768 ,  C12N7/00 ,  A61K39/395 ,  A61K9/00

CPC classification number: A61K35/768 ,  A61K9/0019 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/54 ,  A61K2039/572 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  A61K2300/00

Abstract: The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.

Abstract translation: 本发明涉及治疗肿瘤的方法，包括通过直接注射或全身给药或将肿瘤内施用于肿瘤或癌症与通过全身途径共同施用免疫刺激剂一起递送溶瘤病毒或溶瘤病毒RNA至 哺乳动物。

公开(公告)号：US20160250268A1

公开(公告)日：2016-09-01

申请号：US14869440

申请日：2015-09-29

Applicant: VIRALYTICS LIMITED

Inventor： Darren R. Shafren

IPC: A61K35/768 ,  A61K9/00 ,  C12Q1/02 ,  C12N7/00

CPC classification number: A61K35/768 ,  A61K9/0019 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  C12Q1/025 ,  G01N33/5011

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.

Abstract translation: 公开了使用识别细胞粘附分子和补体调节蛋白中的至少一种的病毒来杀死异常细胞如恶性细胞（包括黑素瘤细胞）的方法。 病毒可能是小核糖核酸病毒科家族的成员。 已经发现柯萨奇A组病毒特别合适。 细胞粘附分子理想地是免疫球蛋白（Ig）超家族的成员。 通常，补体调节蛋白将是DAF。

公开(公告)号：US20150273002A1

公开(公告)日：2015-10-01

申请号：US14579826

申请日：2014-12-22

Applicant: Viralytics Limited

Inventor： Gough Geoffrey Au ,  Darren Raymond Shafren

IPC: A61K35/768 ,  C12N7/00 ,  A61K45/06

CPC classification number: A61K35/768 ,  A61K39/125 ,  A61K45/06 ,  C12N7/00 ,  C12N2770/32032 ,  C12N2770/32321 ,  C12N2770/32332 ,  Y02A50/463 ,  Y02A50/466

Abstract: The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.

Abstract translation: 本发明涉及用于治疗患有血液癌症的受试者的溶瘤微小RNA病毒和方法和组合物。 这些包括用于治疗骨髓瘤的方法和组合物，使用所公开的微小RNA病毒如柯萨奇病毒，在移植之前直接或间接给予受试者的方法和离体清除自体移植物内的恶性细胞。

公开(公告)号：US20150037287A1

公开(公告)日：2015-02-05

申请号：US14231528

申请日：2014-03-31

Applicant: Viralytics Limited

Inventor： Darren R. Shafren

IPC: A61K35/76 ,  C12N7/00

CPC classification number: A61K35/768 ,  A61K9/0019 ,  C12N7/00 ,  C12N2770/32332 ,  C12N2770/32333 ,  C12N2770/32371 ,  C12Q1/025 ,  G01N33/5011

Abstract: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.